ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0380

Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi

W. Benjamin Nowell1, Cassie Clinton2, Fenglong Xie2, Yuji Su3, Laura Stradford1, David Curtis4, Patrick Zueger5, Pankaj Patel6, Kelly Gavigan7, Shilpa Venkatachalam8, Esteban Rivera9 and Jeffrey R. Curtis3, 1Global Healthy Living Foundation, Nyack, NY, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham and Illumination Health, Birmingham, AL, 4Global Healthy Living Foundation, San Francisco, CA, 5AbbVie, Inc., Mettawa, IL, 6AbbVie, Inc., North Chicago, IL, 7Global Healthy Living Foundation, Upper Nyack, NY, 8Global Healthy Living Foundation, New York, NY, 9Global Healthy Living Foundation, Long Island City, NY

Meeting: ACR Convergence 2023

Keywords: rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Although the use of patient-reported outcome (PRO) data has grown more common in the care of people with rheumatoid arthritis (RA), the utility of PRO data captured between visits in relation to traditional, physician-derived measures has not been adequately evaluated. We compared changes over time in PRO data captured on a smartphone app against a physician-derived disease activity measure, the Clinical Disease Activity Index (CDAI).

Methods: RA patients in moderate or high disease activity (CDAI >10) and prescribed either upadacitinib (UPA) or adalimumab (ADA) were enrolled in the study from March 2021 to October 2022 during in-office visits at 28 community rheumatology clinics in the US. Patients were prompted to download the ArthritisPower registry smartphone app to complete PROs at home over a 12-week period. Following a mandatory run-in period to verify willingness to provide PRO data, subsequent at-home data collection included disease activity measures as well as symptom measures from the Patient-Reported Outcomes Measurement Information System (PROMIS). Patients returned for a follow-up clinical visit at approximately 3-4 months (follow-up visits permitted at 2-6 months). Rheumatology clinics provided baseline clinical data including CDAI, years since RA diagnosis, prior medications, and follow-up CDAI. A subgroup analysis was restricted to those who stayed on medication with minimal interruptions. Linear regression models adjusted for baseline CDAI and baseline PRO scores were used to test the correlation between follow-up CDAI and follow-up PRO scores.

Results: Of 299 patients recruited, 240 patients (80%) successfully completed the run-in period, and 205 patients started UPA or ADA within 4 weeks and were eligible. A total of 148 patients (“All” cohort) to date have provided baseline and follow-up clinical and PRO data, and 122 (82%) remained adherent (Table 1). Mean CDAI improved 14.4 units for patients who stayed on the medication (Table 2). Correlations between follow-up CDAI and follow-up PROs ranged from 0.38 – 0.56, the strongest of which were for Patient Global Assessment NRS (R=0.56) and Pain NRS (R=0.47) (Table 3). The adjusted R2 of the overall model showed that changes in PROs explained 52% of the variability in the change in the CDAI.

Conclusion: PROs are useful for tracking RA disease activity over time outside of the clinic setting for patients initiating new treatments, even in the absence of clinician-derived measures.

Supporting image 1

*Adherence to medication was defined as: still taking upadacitinib or adalimumab at 3-month follow-up and no interruption in taking the medication lasting greater than 3 weeks between enrollment to follow-up; RA = rheumatoid arthritis; csDMARD = conventional synthetic disease modifying anti-rheumatic drug; TNFi = tumor necrosis factor inhibitor; JAKi = Janus kinase inhibitor
All categorical data shown as n (%), all continuous data shown as mean (standard deviation [SD])
**RADAI-5 score: 0.0_1.4 for a remission-like state, 1.6_3.0 for mild disease activity, 3.2-5.4 for moderate, and 5.6_10.0 for high disease activity
PROMIS measures use a weekly referent; score of 50.0 is US population mean for all adults, 10.0 is equivalent to 1 standard deviation from the mean
PRO = patient reported outcome; NRS = Numeric rating scale; PROMIS = patient reported outcomes measurement information system; RADAI = rheumatic arthritis disease activity index

Supporting image 2

*RADAI-5 score: 0.0_1.4 for a remission-like state, 1.6_3.0 for mild disease activity, 3.2-5.4 for moderate, and 5.6_10.0 for high disease activity
PROMIS measures use a weekly referent; score of 50.0 is US population mean for all adults, 10.0 is equivalent to 1 standard deviation from the mean
PRO = patient reported outcome; NRS = Numeric rating scale; PROMIS = patient reported outcomes measurement information system; RADAI = rheumatic arthritis disease activity index

Supporting image 3

CDAI = clinical disease activity index; PRO = patient reported outcome; RADAI = rheumatoid arthritis disease activity index


Disclosures: W. Nowell: AbbVie/Abbott, 2, 5, Amgen, 5, Janssen, 2, 5, Scipher Medicine, 5; C. Clinton: None; F. Xie: None; Y. Su: None; L. Stradford: Global Healthy Living Foundation, 3; D. Curtis: Global Healthy Living Foundation, 3; P. Zueger: AbbVie/Abbott, 3, 11; P. Patel: AbbVie/Abbott, 3, 11; K. Gavigan: Global Healthy Living Foundation, 3; S. Venkatachalam: Global Healthy Living Foundation, 3; E. Rivera: Global Healthy Living Foundation, 3; J. Curtis: AbbVie/Abbott, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, CorEvitas, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Labcorp, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi/Regeneron, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Nowell W, Clinton C, Xie F, Su Y, Stradford L, Curtis D, Zueger P, Patel P, Gavigan K, Venkatachalam S, Rivera E, Curtis J. Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/use-of-digital-health-tools-to-evaluate-change-in-clinical-and-patient-reported-outcomes-among-patients-with-rheumatoid-arthritis-initiating-treatment-with-a-jaki-or-tnfi/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-digital-health-tools-to-evaluate-change-in-clinical-and-patient-reported-outcomes-among-patients-with-rheumatoid-arthritis-initiating-treatment-with-a-jaki-or-tnfi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology